Abstract |
A study lasting 1 year assessed the effectiveness and tolerance of depot neuroleptic treatment with pipothiazine palmitate in 52 patients suffering from schizophrenia or related conditions (17 acute and 35 chronic). A 100 mg dose was given to 31 patients and 50 mg to 21 patients: 40 patients received injections 4-weekly, 8 patients 3-weekly and 4 patients 2-weekly. Duration of treatment ranged from 3 to 12 months, involving a total of 347 patient-months. The significant improvement produced by pipothiazine palmitate as shown by patient assessment, based on the Parkside Behaviour Rating Scale (p less than 0.05), a Hamilton-based affect scale (p less than 0.05) and a global rating scale of affect and psychomotor activity (p less than 0.01). Most target symptoms were relieved. A particularly favourable affective response was noted. The incidence of adverse reactions was low and did not present major problems; 6 cases of dystonic reaction were seen, but dealt with promptly and effectively.
|
Authors | K Schmidt |
Journal | Current medical research and opinion
(Curr Med Res Opin)
Vol. 10
Issue 5
Pg. 326-9
( 1986)
ISSN: 0300-7995 [Print] England |
PMID | 2880694
(Publication Type: Journal Article)
|
Chemical References |
- Antipsychotic Agents
- Phenothiazines
- Thiazines
|
Topics |
- Adolescent
- Adult
- Antipsychotic Agents
(administration & dosage)
- Drug Administration Schedule
- Female
- Humans
- Male
- Middle Aged
- Phenothiazines
- Psychiatric Status Rating Scales
- Psychomotor Performance
(drug effects)
- Schizophrenia
(drug therapy, pathology)
- Thiazines
(administration & dosage, adverse effects)
|